Back to Search
Start Over
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV.
- Source :
-
The Journal of infectious diseases [J Infect Dis] 2024 Aug 16; Vol. 230 (2), pp. 421-425. - Publication Year :
- 2024
-
Abstract
- We studied the association of mitochondrial DNA (mtDNA) haplogroups with weight and body mass index (BMI) gain at 96 weeks in 1019 treatment-naive persons with HIV (PWH) who initiated first-line antiretroviral therapy (ART) since 2014. The mean increase in weight and BMI over the study period was 2.90 kg and 0.98 kg/m2, respectively. We found a significant adjusted association between the major UK mtDNA haplogroup and lower weight and BMI increase at 96 weeks after ART initiation. Our findings reveal a potential role for mitochondrial genetics in the complex phenomenon of weight gain after initial ART in PWH.<br />Competing Interests: Potential conflicts of interest. J. B. reports honoraria for advice or public speaking from Gilead, Glaxo Smith Kline (GSK), Janssen, Merck Sharp & Dohme (MSD), ViiV Healthcare; and grants from Gilead, MSD, and ViiV Healthcare. I. J. reports honoraria for advice or public speaking from Gilead and ViiV Healthcare; grants from MSD; and support for attending meetings and/or travel from Gilead. J. C. L. reports honoraria for advice or public speaking from Gilead, MSD, and ViiV Healthcare; grants from ViiV Healthcare; and support for attending meetings and/or travel from ViiV Healthcare and MSD. P. D. reports honoraria for advice or public speaking from Gilead, MSD, Janssen, and ViiV Healthcare. A. P.-M. reports honoraria for public speaking and support for attending meetings and/or travel from Gilead, MSD, Jannsen, and ViiV Healthcare. S. M. reports honoraria for advice or public speaking from Gilead, GSK, Janssen, MSD, and ViiV Healthcare; and grants from Gilead, MSD, and ViiV Healthcare. M. L. M. reports honoraria for advice or public speaking from AbbVie, BMS, Gilead, Jannsen, and ViiV Healthcare; and support for attending meetings and/or travel from ViiV Healthcare and Janssen. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Subjects :
- Humans
Male
Female
Adult
Middle Aged
Anti-HIV Agents therapeutic use
Anti-HIV Agents adverse effects
Mitochondria genetics
Mitochondria drug effects
United Kingdom epidemiology
HIV Infections drug therapy
HIV Infections genetics
Weight Gain drug effects
Weight Gain genetics
DNA, Mitochondrial genetics
Haplotypes
Body Mass Index
Subjects
Details
- Language :
- English
- ISSN :
- 1537-6613
- Volume :
- 230
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- The Journal of infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 38557859
- Full Text :
- https://doi.org/10.1093/infdis/jiae168